N. Scott Fine - 14 Jul 2025 Form 3 Insider Report for Rafael Holdings, Inc. (RFL)

Role
Director
Signature
Joyce J. Mason, by Power of Attorney
Issuer symbol
RFL
Transactions as of
14 Jul 2025
Net transactions value
$0
Form type
3
Filing time
22 Jul 2025, 15:52:38 UTC
Previous filing
05 Jun 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FINE N SCOTT Director C/O RAFAEL HOLDINGS, INC., 520 BROAD STREET, NEWARK Joyce J. Mason, by Power of Attorney 22 Jul 2025 0001163556

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RFL Class B Common Stock, par value $.01 per share 335,348 14 Jul 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RFL Stock Option (right to buy) 14 Jul 2025 Class B Common Stock 20,197 $21.16 Direct F2
holding RFL Stock Option (right to buy) 14 Jul 2025 Class B Common Stock 26,403 $9.25 Direct F2
holding RFL Stock Option (right to buy) 14 Jul 2025 Class B Common Stock 34,792 $3.63 Direct F2
holding RFL Stock Option (right to buy) 14 Jul 2025 Class B Common Stock 93,884 $3.63 Direct F2
holding RFL Stock Option (right to buy) 14 Jul 2025 Class B Common Stock 80,000 $1.90 Direct
holding RFL Class B Common Stock Warrant (Right to Buy) 14 Jul 2025 Class B Common Stock 813 $184.10 Direct F2, F3
holding RFL Class B Common Stock Warrant (Right to Buy) 14 Jul 2025 Class B Common Stock 1,763 $42.56 Direct F2, F3
holding RFL Class B Common Stock Warrant (Right to Buy) 14 Jul 2025 Class B Common Stock 116,093 $2.70 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 331,823 shares of Class B common stock held directly by the Reporting Person and 3,525 shares of Class B common stock held jointly by the Reporting Person and his wife.
F2 The shares, options and warrants were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025.
F3 These warrants are held jointly by the Reporting Person and his wife.